Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Establishing laboratory reference ranges for adults and children in Kilifi, Kenya
Downs LO. et al, (2024)
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS medicine, 21
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)
Maitland K. et al, (2024), Wellcome Open Research, 8, 484 - 484
Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.
Kiguli S. et al, (2024), EClinicalMedicine, 72
A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial)
Maitland K. et al, (2024), Wellcome Open Research, 9, 281 - 281
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
[A global core outcome measurement set for snakebite clinical trials].
Abouyannis M. et al, (2023), Medecine tropicale et sante internationale, 3
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi D. et al, (2023), The Lancet. Infectious diseases, 23, 974 - 982
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
A global core outcome measurement set for snakebite clinical trials
Abouyannis M. et al, (2023), The Lancet Global Health, 11, e296 - e300
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO. et al, (2023), Science translational medicine, 15
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Sang S. et al, (2023), Wellcome open research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome open research, 8
Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial
Wamae K. et al, (2022), Wellcome Open Research, 7, 95 - 95
Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response
Kapulu MC. et al, (2022), BMC Infectious Diseases, 22
A pragmatic randomized controlled trial of standard care versus steroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA)
Lucinde R. et al, (2022), Wellcome Open Research, 7, 269 - 269